JP2009178162A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009178162A5 JP2009178162A5 JP2009068078A JP2009068078A JP2009178162A5 JP 2009178162 A5 JP2009178162 A5 JP 2009178162A5 JP 2009068078 A JP2009068078 A JP 2009068078A JP 2009068078 A JP2009068078 A JP 2009068078A JP 2009178162 A5 JP2009178162 A5 JP 2009178162A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- peptide
- medicament
- amyloid deposition
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000124008 Mammalia Species 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 206010001897 Alzheimer's disease Diseases 0.000 claims 2
- 210000003169 Central Nervous System Anatomy 0.000 claims 2
- 206010057668 Cognitive disease Diseases 0.000 claims 2
- 230000001149 cognitive Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Claims (7)
- 中枢神経系における異常なアミロイド沈着を罹患する哺乳動物において、認知不全を減弱するための組成物であって、該組成物は、認知不全を減弱するのに有効な量のＡβペプチドを含有する、組成物。
- 前記異常なアミロイド沈着がＡβ沈着である、請求項１に記載の組成物。
- 前記ＡβペプチドがＡβ４２である、請求項１または２に記載の組成物。
- 前記哺乳動物が、アルツハイマー病に罹患しているヒトである、請求項１〜３のいずれか１項に記載の組成物。
- 中枢神経系において異常なアミロイド沈着を罹患している哺乳動物において認知不全を減弱するための医薬の製造のためのＡβペプチドの使用。
- 前記ＡβペプチドがＡβ４２である、請求項５に記載の使用。
- 前記医薬がアルツハイマー病の予防または処置のための医薬である、請求項５または６に記載の使用。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21253400P | 2000-06-20 | 2000-06-20 | |
| US60/212,534 | 2000-06-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002503093A Division JP4938956B2 (ja) | 2000-06-20 | 2001-06-19 | 神経変性性障害のトランスジェニック動物モデル |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009178162A JP2009178162A (ja) | 2009-08-13 |
| JP2009178162A5 true JP2009178162A5 (ja) | 2011-07-28 |
| JP5070236B2 JP5070236B2 (ja) | 2012-11-07 |
Family
ID=22791418
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002503093A Expired - Lifetime JP4938956B2 (ja) | 2000-06-20 | 2001-06-19 | 神経変性性障害のトランスジェニック動物モデル |
| JP2009068078A Expired - Lifetime JP5070236B2 (ja) | 2000-06-20 | 2009-03-19 | 神経変性性障害のトランスジェニック動物モデル |
| JP2011132718A Withdrawn JP2011172600A (ja) | 2000-06-20 | 2011-06-14 | 神経変性性障害のトランスジェニック動物モデル |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002503093A Expired - Lifetime JP4938956B2 (ja) | 2000-06-20 | 2001-06-19 | 神経変性性障害のトランスジェニック動物モデル |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011132718A Withdrawn JP2011172600A (ja) | 2000-06-20 | 2011-06-14 | 神経変性性障害のトランスジェニック動物モデル |
Country Status (13)
| Country | Link |
|---|---|
| EP (3) | EP1292187B1 (ja) |
| JP (3) | JP4938956B2 (ja) |
| AT (2) | ATE323408T1 (ja) |
| AU (1) | AU2001270377A1 (ja) |
| CA (1) | CA2407847C (ja) |
| CY (1) | CY1105122T1 (ja) |
| DE (2) | DE60118913T2 (ja) |
| DK (1) | DK1292187T3 (ja) |
| ES (1) | ES2262662T3 (ja) |
| MX (1) | MXPA02011516A (ja) |
| PT (1) | PT1292187E (ja) |
| SI (1) | SI1292187T1 (ja) |
| WO (1) | WO2001097607A2 (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100994748B1 (ko) | 2002-04-19 | 2010-11-17 | 더 가버닝 카운실 오브 더 유니버시티 오브 토론토 | 알쯔하이머병의 치료를 위한 면역학적 방법 및 조성물 |
| US7544855B2 (en) * | 2004-04-23 | 2009-06-09 | Buck Institute | Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664 |
| JP4590638B2 (ja) * | 2006-03-20 | 2010-12-01 | 国立大学法人鳥取大学 | 家族性筋萎縮性側索硬化症（ｆａｌｓ）発症するトランスジェニックマウス |
| CL2007002908A1 (es) | 2007-10-09 | 2008-05-30 | Univ Concepcion | Procedimiento electroquimico in vitro para evaluar capacidad neurotoxica de estructuras, principios activos y/o compuestos de interes en celulas vivas y que comprende medir y cuantificar los parametros electricos en membranas expuestas a dichos agreg |
| CA2703727A1 (en) * | 2007-11-01 | 2009-05-07 | F. Hoffmann-La Roche Ag | Quadruple transgenic non-human animal |
| WO2010054324A2 (en) * | 2008-11-10 | 2010-05-14 | The Regents Of The University Of Colorado, A Body Corporate | Methods for treating clinical conditions associated with lipoprotein lipase activity |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09507746A (ja) | 1993-10-27 | 1997-08-12 | アテナ ニューロサイエンシズ，インコーポレイティド | Ｓｗｅｄｉｓｈ変異を有するＡＰＰ対立遺伝子を含有するトランスジェニック動物 |
| JPH07132033A (ja) | 1993-11-12 | 1995-05-23 | Hoechst Japan Ltd | アルツハイマー病モデルトランスジェニック動物 |
| ATE278023T1 (de) * | 1994-01-27 | 2004-10-15 | Univ Minnesota | Nicht humane, transgenische säugetiere mit sich entwickelnder neurologischer krankheit |
| US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
| CA2221986A1 (en) * | 1995-06-07 | 1996-12-19 | Athena Neurosciences, Inc. | Method for identifying alzheimer's disease therapeutics using transgenic animal models |
| US5894078A (en) | 1996-02-26 | 1999-04-13 | Advanced Bioconcept, Inc. | Transgenic mouse expressing C-100 app |
| WO1999009150A1 (en) * | 1996-08-15 | 1999-02-25 | Bayer Corporation | Method of introducing modifications into a gene |
| US5898094A (en) | 1996-10-21 | 1999-04-27 | University Of South Florida | Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
-
2001
- 2001-06-19 ES ES01949132T patent/ES2262662T3/es not_active Expired - Lifetime
- 2001-06-19 MX MXPA02011516A patent/MXPA02011516A/es not_active Application Discontinuation
- 2001-06-19 EP EP01949132A patent/EP1292187B1/en not_active Expired - Lifetime
- 2001-06-19 DK DK01949132T patent/DK1292187T3/da active
- 2001-06-19 CA CA2407847A patent/CA2407847C/en not_active Expired - Lifetime
- 2001-06-19 WO PCT/CA2001/000900 patent/WO2001097607A2/en active IP Right Grant
- 2001-06-19 AT AT01949132T patent/ATE323408T1/de not_active IP Right Cessation
- 2001-06-19 AT AT06007794T patent/ATE499832T1/de not_active IP Right Cessation
- 2001-06-19 DE DE60118913T patent/DE60118913T2/de not_active Expired - Lifetime
- 2001-06-19 EP EP10182160.1A patent/EP2263453B1/en not_active Expired - Lifetime
- 2001-06-19 PT PT01949132T patent/PT1292187E/pt unknown
- 2001-06-19 JP JP2002503093A patent/JP4938956B2/ja not_active Expired - Lifetime
- 2001-06-19 SI SI200130579T patent/SI1292187T1/sl unknown
- 2001-06-19 EP EP06007794A patent/EP1728423B1/en not_active Expired - Lifetime
- 2001-06-19 AU AU2001270377A patent/AU2001270377A1/en not_active Abandoned
- 2001-06-19 DE DE60144164T patent/DE60144164D1/de not_active Expired - Lifetime
-
2006
- 2006-07-19 CY CY20061101003T patent/CY1105122T1/el unknown
-
2009
- 2009-03-19 JP JP2009068078A patent/JP5070236B2/ja not_active Expired - Lifetime
-
2011
- 2011-06-14 JP JP2011132718A patent/JP2011172600A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017075173A5 (ja) | ||
| EP3563849A3 (en) | Combination therapies for the treatment of alzheimer's disease and related disorders | |
| JP2009178162A5 (ja) | ||
| EA201890313A1 (ru) | Гуманизированные антитела к пироглутаматному варианту бета-амилоида | |
| MY164376A (en) | Phosphospecific antibodies recognizing tau | |
| NO20084531L (no) | Bruk av flibanserin for behandling av post-menopause seksuell lyst lidelser | |
| EA200870556A1 (ru) | Комбинированная терапия в лечении эпилепсии и родственных расстройств | |
| MX354662B (es) | Anticuerpos fosfoespecificos que reconocen la tau. | |
| JP2015501783A5 (ja) | ||
| GT201100283A (es) | Anticuerpos humanizados especificos de la forma protofibrilar del péptido beta-amiloide | |
| MY164579A (en) | Safe and functional humanized antibodies | |
| EA201291336A1 (ru) | Замещенные 5-фтор-1н-пиразолопиридины и их применение | |
| MD3478712T2 (ro) | Anticorpi peptidici beta amiloizi anti-N3pGlu și utilizări ale acestora | |
| MY171300A (en) | Pharmaceutical composition | |
| NO20081527L (no) | Anvendelse av flibanserin for behandling av pre-menopausal seksuell lyst forstyrrelser | |
| JP2011520900A5 (ja) | ||
| WO2009149486A3 (en) | Compounds for treating beta-amyloidoses | |
| SMT201500189T1 (it) | Ligandi sigma per la prevenzione o il trattamento del dolore indotto da chmioterapia | |
| JP2009505979A5 (ja) | ||
| MX2020012932A (es) | Nuevos compuestos para diagnostico. | |
| MX2014001088A (es) | Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas. | |
| JP2016512817A5 (ja) | ||
| EP4285993A3 (en) | Growth differentiation factor 15 as biomarker for metformin | |
| WO2011072257A3 (en) | Amyloid binding agents | |
| RU2014148305A (ru) | Камсилатная соль |